Peptide Monograph
BPC-157
Body Protection Compound-157
At a Glance
Mechanism of Action
BPC-157 is a synthetic pentadecapeptide composed of 15 amino acids, derived from a segment of the human gastric juice protein known as Body Protection Compound. It is a partial sequence of this larger protective protein and is stable in human gastric juice, distinguishing it from many other peptides that degrade rapidly in the gastrointestinal environment.[1]
The peptide exerts its effects through several interconnected molecular pathways. BPC-157 promotes angiogenesis (the formation of new blood vessels), which is critical for tissue repair, by upregulating vascular endothelial growth factor (VEGF) expression and modulating the VEGFR2-Akt-eNOS signaling pathway.[2] This pro-angiogenic activity underlies much of its observed healing capacity across diverse tissue types.
A central feature of BPC-157's pharmacology is its interaction with the nitric oxide (NO) system. The peptide modulates both constitutive and inducible nitric oxide synthase (NOS) activity, and experimental evidence demonstrates that it can counteract NOS-blocker-induced disturbances as well as excessive NO release caused by L-arginine or NOS-substrate overload.[3] This bidirectional modulation of the NO system may account for its protective effects across multiple organ systems.
BPC-157 also acts on the FAK-paxillin pathway, a key signaling cascade involved in cell adhesion, migration, and proliferation. By activating focal adhesion kinase (FAK) and its downstream effector paxillin, BPC-157 enhances tendon fibroblast migration and promotes organized collagen fiber formation, which is essential for tendon and ligament repair.[4]
Additionally, BPC-157 upregulates growth factor expression, including epidermal growth factor (EGF) receptor and its downstream signaling, and influences the expression of early growth response gene 1 (EGR-1) and its repressor nerve growth factor 1-A binding protein-2 (NAB2). This growth factor modulation promotes granulation tissue formation and accelerates the healing cascade.[1][5]
The peptide has also demonstrated interactions with the dopaminergic system, providing protective effects against dopaminergic neurotoxins, and with the GABAergic system, suggesting a broader neuromodulatory profile beyond simple tissue repair.[3]
Evidence Summary
The vast majority of BPC-157 research has been conducted in animal models (primarily rats). As of this writing, no completed, peer-reviewed, randomized controlled human trials have been published. All claims about efficacy and safety in humans are extrapolated from preclinical data and anecdotal reports. Readers should weigh this limitation heavily when evaluating the evidence presented below.
Animal and In Vitro Studies
BPC-157 has been studied extensively in rat models across a wide range of tissue injury contexts. Sikiric et al. demonstrated that BPC-157 accelerates healing of transected rat Achilles tendons with improved biomechanical properties, including greater tensile strength and load to failure, compared to controls.[4] Comparable results have been shown in models of muscle crush injury, where BPC-157 accelerated functional recovery and reduced inflammation markers.[1]
In gastrointestinal models, BPC-157 has shown strong cytoprotective properties. It protects against ethanol-induced gastric lesions, NSAID-induced gastrointestinal damage, and experimentally induced inflammatory bowel disease in rats. The peptide reduces lesion size, accelerates mucosal healing, and attenuates inflammatory cytokine release.[5][6]
Additional preclinical findings include protective effects in models of liver damage (CCl4 and alcohol-induced), corneal injury, periodontitis, nerve transection, and spinal cord injury. Across these diverse models, BPC-157 consistently demonstrates anti-inflammatory, pro-angiogenic, and tissue-protective actions.[2][3]
Human Evidence
To date, no completed phase II or phase III randomized controlled trials of BPC-157 in humans have been published in peer-reviewed literature. An early clinical trial (PL 14736) explored an oral formulation for inflammatory bowel disease, but results were limited and not published in full. Anecdotal reports from self-experimenters in online communities describe subjective improvements in joint pain, tendon injuries, and gastrointestinal symptoms, but these reports carry substantial risk of placebo effect and reporting bias and cannot be considered reliable evidence.
The absence of human clinical data means that the therapeutic index, optimal dosing, and true adverse event profile of BPC-157 in humans remain unknown. Any use outside of supervised clinical research is speculative.
Primary Uses (in Research)
Based on the available preclinical literature, BPC-157 has been investigated for the following applications:
- Tendon and ligament healing — Accelerated repair of transected and detached tendons in rat models, with improved biomechanical endpoints including tensile strength and collagen organization.[4]
- Gastrointestinal mucosal protection — Cytoprotection against NSAID-induced, ethanol-induced, and stress-induced gastric and intestinal lesions; accelerated healing of experimental ulcers.[5][6]
- Inflammatory bowel disease — Reduction of intestinal inflammation, improved mucosal integrity, and attenuation of inflammatory cytokines in rat models of colitis and short bowel syndrome.[6]
- Muscle injury recovery — Accelerated functional recovery and reduced inflammation in rat models of muscle crush injury and transection.[1]
- Bone and joint repair — Improved fracture healing and protection against experimentally induced osteoporosis in preclinical models.[2]
- Neuroprotection — Protective effects against dopaminergic neurotoxins, peripheral nerve transection, and traumatic brain injury in animal models.[3]
Contraindications
No established human contraindications exist because insufficient clinical data is available. The following precautions are based on the peptide's known pharmacological mechanisms and represent theoretical concerns:
- Pregnancy and lactation — No reproductive toxicology or teratogenicity studies have been conducted in humans. No safety data exists for use during pregnancy or breastfeeding. Use is strongly discouraged.
- Active malignancy — BPC-157 promotes angiogenesis and upregulates growth factor expression. Theoretically, this could accelerate tumor vascularization or growth in individuals with active cancer, though this has not been demonstrated in studies.
- Concomitant anticoagulant therapy — The pro-angiogenic effects of BPC-157 may theoretically interact with anticoagulant medications. Patients on warfarin, heparins, or direct oral anticoagulants should exercise caution.
- Pediatric use — No safety or efficacy data exists for use in children or adolescents.
- Known hypersensitivity — Discontinue use if signs of allergic reaction (rash, urticaria, angioedema, dyspnea) develop.
Standard Protocols
The following protocols are derived from animal study dosing extrapolations and community-reported protocols. No dosing regimen has been validated in human clinical trials. These should not be interpreted as medical prescriptions.
| Protocol | Route | Dose | Frequency | Duration |
|---|---|---|---|---|
| Tissue repair (general) | SubQ (local to injury) | 250 – 500 mcg | 1–2x daily | 4–6 weeks |
| GI protection / healing | Oral | 250 – 500 mcg | 2x daily (empty stomach) | 4–8 weeks |
| Systemic recovery | SubQ (abdomen) | 200 – 300 mcg | 1x daily | 4 weeks |
| Tendon/ligament focus | SubQ (peritendinous) | 300 – 500 mcg | 2x daily | 4–12 weeks |
Common Stacks & Synergies
In the peptide research and self-experimentation community, BPC-157 is frequently combined with other compounds. The following stacks are commonly discussed but have no published human clinical evidence supporting their combined use:
- BPC-157 + TB-500 — The most commonly reported combination. The rationale is that BPC-157's pro-angiogenic and growth-factor-mediated healing complements TB-500's actin-upregulation and cell-migration-promoting effects. Some preclinical data supports complementary mechanisms, but no controlled studies have evaluated the combination.
- BPC-157 + GHK-Cu — Copper peptide GHK-Cu is used topically or via injection for wound healing. The theoretical synergy involves BPC-157 promoting deep tissue repair while GHK-Cu enhances extracellular matrix remodeling.
- BPC-157 + Collagen/Vitamin C — Oral collagen and ascorbic acid are commonly used alongside BPC-157 to provide structural building blocks for connective tissue synthesis.
Preparation & Administration
BPC-157 is supplied as a lyophilized (freeze-dried) powder in vials, typically containing 5 mg or 10 mg of peptide. It must be reconstituted with bacteriostatic water (BAC water) before injection.
Reconstitution
For a standard 5 mg vial reconstituted with 2 mL of bacteriostatic water, each 0.1 mL (10 units on a standard insulin syringe) delivers 250 mcg. For detailed step-by-step reconstitution instructions and a concentration calculator, see the Reconstitution Guide.
Injection
Subcutaneous injections should be administered using a 29–31 gauge insulin syringe. For localized injuries, inject as close to the injury site as anatomically practical. Rotate injection sites to avoid lipodystrophy. For injection technique, site selection, and sterile procedure, see the Injection Safety Guide.
Oral Administration
BPC-157's stability in gastric acid is unusual among peptides and makes oral administration a viable route, particularly for GI-related applications. Oral BPC-157 is typically taken on an empty stomach. Bioavailability comparisons between oral and injectable routes remain an open research question.
Side Effects & Adverse Events
The adverse event profile described below is drawn from animal toxicology studies and uncontrolled self-reports. Without formal human clinical trials, the true incidence and severity of side effects cannot be established.
In animal studies, BPC-157 has demonstrated a notably favorable safety profile. Toxicology studies in rats have not identified a lethal dose (LD1 not achieved), and no organ toxicity has been observed at doses many orders of magnitude above the pharmacologically active range.[1][5]
Self-reported side effects from community use (unverified):
- Injection site redness, swelling, or mild pain (most commonly reported)
- Mild nausea, particularly with oral administration
- Dizziness or lightheadedness (infrequent)
- Fatigue (rare)
- Headache (rare)
No serious adverse events have been reported in published animal literature or in widely circulated community reports, though the absence of systematic pharmacovigilance means rare or delayed adverse effects could go undetected.
Drug Interactions
No formal drug interaction studies have been conducted with BPC-157 in humans. The following theoretical interactions are based on the peptide's known pharmacological mechanisms:
- Anticoagulants (warfarin, heparin, DOACs) — BPC-157's pro-angiogenic properties and effects on the NO system could theoretically modify bleeding risk or interact with anticoagulant pharmacodynamics. Exercise caution and monitor closely if combining.
- NSAIDs (ibuprofen, naproxen, aspirin) — Animal data suggests BPC-157 may have synergistic GI-protective effects with NSAIDs, potentially counteracting NSAID-induced gastropathy. This does not constitute clinical evidence for co-administration.[6]
- Corticosteroids — BPC-157 has shown protective effects against corticosteroid-induced impairment of healing in animal models. Whether this translates to a clinically meaningful interaction in humans is unknown.
- Dopaminergic agents — Given BPC-157's interaction with dopamine systems in animal models, theoretical interactions with L-DOPA, dopamine agonists, or antipsychotics are possible.[3]
Storage & Handling
| Form | Condition | Stability |
|---|---|---|
| Lyophilized powder (sealed) | Room temperature (below 25°C / 77°F), away from direct light | Stable for extended periods (months to years if sealed) |
| Lyophilized powder (sealed) | Refrigerated (2–8°C / 36–46°F) | Optimal for long-term storage |
| Reconstituted solution | Refrigerated (2–8°C / 36–46°F) | Use within 28 days |
| Reconstituted solution | Room temperature | Not recommended; use within 24–48 hours if unavoidable |
Do not freeze reconstituted solution. Protect from prolonged light exposure. If the solution appears cloudy, discolored, or contains particulate matter, discard the vial. Always use bacteriostatic water (not sterile water) for reconstitution to provide antimicrobial preservation for multi-dose use.
Legal & Regulatory Status
- FDA (United States) — Not approved for any indication. Not scheduled as a controlled substance. Sold under the research chemical designation "not for human consumption." The FDA has issued warning letters to companies marketing BPC-157 as a dietary supplement or therapeutic agent.
- WADA (World Anti-Doping Agency) — Not specifically listed on the WADA Prohibited List as of 2026, but could potentially fall under S0 ("non-approved substances") depending on interpretation.
- European Union — Not approved as a medicinal product. Regulatory status varies by member state. Generally available as a research chemical.
- Australia (TGA) — Not approved. Classified as a Schedule 4 prescription-only substance under the Poisons Standard.
- Legal gray area — In most jurisdictions, BPC-157 occupies a legal gray area. It is legal to purchase for research purposes but not legal to market for human therapeutic use. The legal landscape varies significantly by country and is subject to change.
Open Questions
Significant gaps remain in the BPC-157 evidence base. Key unresolved questions include:
- Absence of human clinical trials — The most fundamental limitation. Without RCTs, the therapeutic index, dose-response relationship, and true safety profile in humans cannot be determined.
- Optimal dosing — Current dosing protocols are extrapolated from rat studies using allometric scaling, a method with inherent uncertainty. The true optimal dose for any human indication is unknown.
- Oral vs. injectable bioavailability — While BPC-157 is stable in gastric acid (unlike most peptides), the comparative bioavailability of oral versus subcutaneous administration has not been rigorously characterized in humans.
- Long-term safety — No long-term safety data (beyond several weeks) exists for BPC-157 in any species. The consequences of chronic angiogenesis promotion and growth factor upregulation are unknown.
- Cancer risk — The pro-angiogenic and growth-factor-promoting effects raise theoretical concerns about tumor promotion. Whether BPC-157 increases, decreases, or has no effect on cancer risk is unknown.
- Purity and quality control — As an unregulated research chemical, the purity, sterility, and accurate labeling of commercially available BPC-157 products cannot be guaranteed.
Bibliography
- Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Stambolija V, Zoricic Z, Vrcic H, Sebecic B. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Curr Pharm Des. 2011;17(16):1612-32. doi:10.2174/138161211796197205. PMID:21548867.
- Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Aralica G, Saftic I, Suran J. "Stable gastric pentadecapeptide BPC 157-NO-system relation." Curr Pharm Des. 2014;20(7):1126-35. doi:10.2174/13816128113190990411. PMID:23755727.
- Sikiric P, Rucman R, Turkovic B, Sever M, Klicek R, Radic B, Drmic D, Stupnisek M, Misic M, Staroveski M, Seiwerth S. "Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Vascular recruitment and gastrointestinal tract healing." Curr Pharm Des. 2018;24(18):1990-2001. doi:10.2174/1381612824666180608101119. PMID:29879879.
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." J Appl Physiol. 2011;110(3):774-80. doi:10.1152/japplphysiol.00945.2010. PMID:21030672.
- Sikiric P, Seiwerth S, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D. "Revised Robert's cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. Possible significance and implications for novel mediator." Curr Pharm Des. 2010;16(10):1224-34. doi:10.2174/138161210790945977. PMID:20166997.
- Sikiric P, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Jagic V, Turkovic B, Rotkvic I, Mise S, Zoricic I, Konjevoda P, Perovic D, Jurina L, Separovic J, Hanzevacki M, Artukovic B, Bratulic M, Tisljar M, Gjurasin M, Miklic P, Stancic-Rokotov D, Slobodnjak Z, Jelovac N, Marovic A. "The influence of a novel pentadecapeptide BPC 157 on NG-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure." Eur J Pharmacol. 1997;332(1):23-33. doi:10.1016/S0014-2999(97)01033-9. PMID:9298921.
- Vukojevic J, Siroglavic M, Kasnik K, Kralj T, Stancic D, Kokot A, Kolaric D, Drmic D, Sever AZ, Barisic I, Suran J, Seiwerth S, Sikiric P. "Rat inferior caval vein (ICV) ligature and particular pentadecapeptide BPC 157 therapy." Vasc Pharmacol. 2018;106:46-57. doi:10.1016/j.vph.2018.02.010. PMID:29476967.